|
| 1 |
Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Juyoung Shin, Raeun Kim, Hun-Sung Kim
|
|
| 2 |
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
|
|
| 3 |
Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho
Endocrinol Metab.2023;38(1):1-9. Published online 2023 February 13
DOI: http://dx.doi.org/10.3803/EnM.2023.103
|
|
| 4 |
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Adie Viljoen, Stephen C. Bain
Endocrinol Metab.2023;38(1):25-33. Published online 2023 February 6
DOI: http://dx.doi.org/10.3803/EnM.2022.1642
|
|
| 5 |
The effects and side effects of liraglutide as a treatment for obesity
Jeonghoon Ha, Jin Yu, Joonyub Lee, Hun-Sung Kim
|
|
| 6 |
Ca2+ entry through reverse Na+/Ca2+ exchanger in NCI-H716, glucagon-like peptide-1 secreting cells
Kyung Jin Choi, Jin Wook Hwang, Se Hoon Kim, Hyung Seo Park
|
|
| 7 |
Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
Carla Greco, Daniele Santi, Giulia Brigante, Chiara Pacchioni, Manuela Simoni
Diabetes Metab J.2022;46(6):901-911. Published online 2022 April 12
DOI: http://dx.doi.org/10.4093/dmj.2021.0314
|
|
| 8 |
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinol Metab.2022;37(1):74-83. Published online 2022 February 9
DOI: http://dx.doi.org/10.3803/EnM.2021.1293
|
|
| 9 |
DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice
Youjin Kim, Si Woo Lee, Hyejin Wang, Ryeong-Hyeon Kim, Hyun Ki Park, Hangkyu Lee, Eun Seok Kang
Diabetes Metab J.2022;46(2):337-348. Published online 2022 January 21
DOI: http://dx.doi.org/10.4093/dmj.2021.0056
|
|
| 10 |
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J.2022;46(4):658-662. Published online 2021 November 8
DOI: http://dx.doi.org/10.4093/dmj.2021.0232
|
|
| 11 |
Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist
Hae Jin Kim
|
|
| 12 |
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh
Endocrinol Metab.2021;36(3):647-660. Published online 2021 June 18
DOI: http://dx.doi.org/10.3803/EnM.2020.934
|
|
| 13 |
Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
Endocrinol Metab.2021;36(2):256-269. Published online 2021 April 19
DOI: http://dx.doi.org/10.3803/EnM.2021.987
|
|
| 14 |
Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
Hua-Xing Huang, Liang-Lan Shen, Hai-Yan Huang, Li-Hua Zhao, Feng Xu, Dong-Mei Zhang, Xiu-Lin Zhang, Tong Chen, Xue-Qin Wang, Yan Xie, Jian-Bin Su
Diabetes Metab J.2021;45(6):868-879. Published online 2021 March 23
DOI: http://dx.doi.org/10.4093/dmj.2020.0149
|
|
| 15 |
Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
Jin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Lim
Endocrinol Metab.2021;36(1):157-170. Published online 2021 February 24
DOI: http://dx.doi.org/10.3803/EnM.2020.781
|
|
| 16 |
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Hun Jee Choe, Young Min Cho
Endocrinol Metab.2021;36(1):22-29. Published online 2021 February 24
DOI: http://dx.doi.org/10.3803/EnM.2021.102
|
|
| 17 |
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Eun-Jung Rhee, Mee-Kyung Kim, Won-Young Lee
Endocrinol Metab.2021;36(1):41-50. Published online 2021 February 24
DOI: http://dx.doi.org/10.3803/EnM.2021.106
|
|
| 18 |
Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon
|
|
| 19 |
Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus
Jae Hyun Bae, Hyung Jin Choi, Kang Ik Kevin Cho, Lee Kyung Kim, Jun Soo Kwon, Young Min Cho
Diabetes Metab J.2020;44(2):248-259. Published online 2019 November 4
DOI: http://dx.doi.org/10.4093/dmj.2019.0018
|
|
| 20 |
Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
Inkuk Lee, Eun Seok Kang
|
|
